On January 8, a pink notice announced that it had recently received a "drug registration certificate" for ammonia hydrochloride injections approved by the State Drug Administration.
company developed ammonia hydrochloride injection adaptation: suitable for acute and chronic lung diseases accompanied by abnormal sputum secretion and poor sputum function.
such as acute exacerbation of chronic bronchitis, wheezing bronchitis and bronchial asthma.
treatment for lung complications after surgery.
treatment for respiratory distress syndrome (IRDS) in premature babies and newborns.
, according to IMS data, the market sales of ammonia bromoso in 2019 were 3,056 million yuan.
According to the website of the State Drug Administration, as of the date of the announcement, domestic drugs including the company including Zhejiang Kangnbe Pharmaceutical Co., Ltd., Chenxin Pharmaceutical Co., Ltd., Guorui Pharmaceutical Co., Ltd., Shandong Luoxin Pharmaceutical Group Co., Ltd., Hainan All-Star Pharmaceutical Co., Ltd. and other 42 enterprises have obtained approval for the production of hydrochloride bromoso injections.